They administered two doses of the vaccine via a nasal spray in animal trials which are the first stage in vaccine development.
This elicited robust antibodies and T cell responses which were enough to be able to neutralize SARS-CoV-2.
There was also a big reduction in lung pathology, inflammation and clinical disease in the rodents who received the vaccine.
The study is published in Preclinical Animal Models. One author is Virologist Dr. Muhammad Munir.
The vaccine is based on a common poultry virus called the Newcastle Disease Virus (NDV), which can replicate in humans but is harmless.
In the study, the team engineered NDV to produce the spike proteins of the SARS-CoV-2 virus which causes COVID-19, tricking the body into mounting an immune response against SARS-CoV-2.
They found that administering this vaccine through a nasal spray completely protected the animals from shedding the virus which causes transmission of the virus.
This means the immunization of the upper respiratory tract through a nasal spray can prevent individuals from spreading the virus and developing infections elsewhere in the body.
A vaccine nasal spray offers several advantages over conventional approaches, including non-invasive administration, the induction of local immunity as well as being an alternative for people afraid of needles or with blood clotting co-morbidities.
There is currently an intranasal influenza vaccine registered for human use so administering a vaccine in this way has already been proven to be effective.